A Yale University study has identified serious weaknesses in how some telehealth providers prescribe GLP-1 weight-loss medications. The secret shopper study examined 49 online healthcare providers. Researchers used a fictional patient who met the clinical criteria for GLP-1 treatment. The findings suggest that several virtual clinics may be prioritising fast access to prescriptions over detailed medical care. This could expose…
Tag: Zepbound
-
Eli Lilly 2026 Guidance Signals Momentum In Obesity Care
Eli Lilly has forecast 2026 profit and revenue above Wall Street expectations, reinforcing how fast the obesity market is reshaping Big Pharma growth plans. The recent Eli Lilly 2026 Guidance reflects the company’s confidence in strong future performance. The company also beat estimates for fourth-quarter earnings, helped by strong demand for its injectable weight-loss and diabetes medicines. For Q4, Lilly…
-
Lilly Hits $1 Trillion Valuation with Weight-Loss Success
In a historic milestone for the pharmaceutical industry, Eli Lilly surged to a market value of $1 trillion on Friday. It became the first drugmaker to join an exclusive club previously dominated by technology heavyweights. This event marked the moment Lilly hit a $1 trillion valuation. It highlighted the company’s rapid ascent as a global powerhouse in the weight-loss sector.…
-
Obesity Drug Deal: Trump Cuts Prices for Patients
US President Donald Trump has announced a landmark deal with drugmakers Novo Nordisk and Eli Lilly, set to significantly reduce the price of hugely popular obesity drugs for millions of Americans. The agreement, unveiled at the White House, will slash costs for injectable treatments like Wegovy and Zepbound, as well as two forthcoming oral medications. The deal aims to save…
-
GLP-1 Drugs Lower Cancer Rates in Weight Loss Study
New findings suggest that popular GLP-1 drugs, widely prescribed for weight loss and type 2 diabetes, may significantly influence a patient’s risk of developing certain cancers. This is mainly for the better. A comprehensive review of medical records has uncovered a compelling link. It found that the use of GLP-1 agonists – such as Ozempic, Wegovy, Mounjaro, and Zepbound –…
-
Novo Nordisk Hiring Freeze After Wegovy Sales Decline
Danish pharmaceutical giant Novo Nordisk, which rode a wave of unprecedented success with its weight-loss drug Wegovy, has announced a global hiring freeze for non-critical roles. This signals a dramatic shift from rapid expansion to rigorous cost-cutting. Sales begin to slow and competition intensifies. Novo Nordisk’s hiring freeze is a significant turn for the company. The Wegovy Hiring Spree The…
-
Weight-Loss Drug Costs Fuel US Employer Healthcare Cuts
More than half of large employers in the United States are planning to reduce their healthcare benefits in 2026. This decision comes as the skyrocketing cost of new weight-loss and specialty medicines puts unprecedented pressure on budgets. The soaring costs of weight-loss drugs are a key concern, according to a new survey. The report, released on Wednesday by consulting firm…
-
Lilly’s Orforglipron Shows Significant Weight Loss in Phase 3 Trial
Eli Lilly has announced promising results from a Phase 3 trial of its oral drug, orforglipron. The trial demonstrated significant efficacy in reducing weight and blood sugar levels in patients with type 2 diabetes. Significant Weight Loss and Blood Sugar Control with Orforglipron In the 40-week study, patients taking orforglipron lost up to 7.9% of their body weight (approximately 16…
-
As competition heats up, Novo Nordisk’s share price declines
Danish pharmaceutical giant Novo Nordisk, renowned for its diabetes and weight loss drugs Ozempic and Wegovy, has experienced a significant share price drop of around 19% this month. This decline follows its market peak in June, driven by increasing competition from Eli Lilly, a key player in the same space. Eli Lilly has gained substantial momentum with its rival drugs,…